First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND
- Written by PR Newswire
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Administration (TGA) in Australia. 9MW3811 is the first...
Read more: First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND